Peel Hunt Reaffirms Buy Rating for Oxford BioMedica (OXB)

Peel Hunt reiterated their buy rating on shares of Oxford BioMedica (LON:OXB) in a research report report published on Thursday.

Shares of Oxford BioMedica stock opened at GBX 701.90 ($9.17) on Thursday. Oxford BioMedica has a one year low of GBX 4.44 ($0.06) and a one year high of GBX 13.19 ($0.17).

In other Oxford BioMedica news, insider John Dawson sold 10,046 shares of the stock in a transaction that occurred on Tuesday, August 7th. The stock was sold at an average price of GBX 890 ($11.63), for a total value of £89,409.40 ($116,829.22). Also, insider Lorenzo Tallarigo purchased 302 shares of the business’s stock in a transaction on Wednesday, August 22nd. The stock was purchased at an average price of GBX 881 ($11.51) per share, for a total transaction of £2,660.62 ($3,476.57). In the last 90 days, insiders have purchased 946 shares of company stock worth $797,907.

About Oxford BioMedica

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Read More: Asset Allocation, Balancing Your Investments

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply